Patents by Inventor Mark Novas
Mark Novas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11246850Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: GrantFiled: May 17, 2021Date of Patent: February 15, 2022Assignee: Biogen MA Inc.Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20210315854Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: May 17, 2021Publication date: October 14, 2021Inventors: Mark Novas, Rui (Ray) Zhang
-
Patent number: 11129806Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: GrantFiled: July 11, 2017Date of Patent: September 28, 2021Assignee: Biogen MA Inc.Inventors: Mark Novas, Rui (Ray) Zhang
-
Patent number: 11007167Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: GrantFiled: October 15, 2020Date of Patent: May 18, 2021Assignee: Biogen MA Inc.Inventors: Mark Novas, Rui (Ray) Zhang
-
Patent number: 11007166Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: GrantFiled: July 22, 2020Date of Patent: May 18, 2021Assignee: BIOGEN MA INC.Inventors: Mark Novas, Rui (Ray) Zhang
-
Patent number: 10959972Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: GrantFiled: October 29, 2018Date of Patent: March 30, 2021Assignee: BIOGEN MA INC.Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20210023040Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: October 15, 2020Publication date: January 28, 2021Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20200345679Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: July 22, 2020Publication date: November 5, 2020Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20190125710Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: October 29, 2018Publication date: May 2, 2019Applicant: Biogen MA Inc.Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20190008817Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: July 24, 2018Publication date: January 10, 2019Applicant: Biogen MA Inc.Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20180000770Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: July 11, 2017Publication date: January 4, 2018Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20170368013Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: July 11, 2017Publication date: December 28, 2017Inventors: Mark Novas, Rui (Ray) Zhang
-
Publication number: 20170354630Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.Type: ApplicationFiled: November 16, 2015Publication date: December 14, 2017Inventors: Mark Novas, Rui (Ray) Zhang
-
Patent number: 9358450Abstract: An interactive education system includes a database storing a common question database and a plurality of user-specific question inventories, a memory storing computer instructions, and a processor configured to execute the computer instructions to perform operations including presenting a game environment between a first user and a second user where the first and second users can throw questions from their respective question inventories or common question database at each other with or without offensive power-ups, and answer the questions thrown by each other with or without defensive power-ups; rewarding the first and second users with credits and points when the first and second users answer the questions correctly; determining which one of the first and second users wins the game based on the respective total number of points achieved by the first and second users; and enabling the first and second users to purchase additional offensive or defensive power-ups with their respective credits.Type: GrantFiled: April 8, 2014Date of Patent: June 7, 2016Inventor: Kenneth Mark Nova
-
Publication number: 20150283455Abstract: An interactive education system includes a database storing a common question database and a plurality of user-specific question inventories, a memory storing computer instructions, and a processor configured to execute the computer instructions to perform operations including presenting a game environment between a first user and a second user where the first and second users can throw questions from their respective question inventories or common question database at each other with or without offensive power-ups, and answer the questions thrown by each other with or without defensive power-ups; rewarding the first and second users with credits and points when the first and second users answer the questions correctly; determining which one of the first and second users wins the game based on the respective total number of points achieved by the first and second users; and enabling the first and second users to purchase additional offensive or defensive power-ups with their respective credits.Type: ApplicationFiled: April 8, 2014Publication date: October 8, 2015Inventor: Kenneth Mark NOVA